MARIA Research Reactor To Be Modernised By 2027 On 20th June 2023, the Council of Ministers of Poland adopted a resolution on the MARIA nuclear research reactor modernisation programme, so as to enable its operation beyond 2027. The MARIA reactor is currently the only and unique research facility of this type in Poland and in…
PSI Leads New Research To Fight Metastatic Prostate Cancer Researchers at the Paul Scherrer Institute (ENS Corporate Member, PSI) are developing a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug, studied by a research consortium involving PSI, the University Hospital Basel and ETH Zurich, is now being…
Full Financing For PALLAS Reactor Announced By Dutch Minister The Dutch Minister of Health, Welfare and Sport Ernst Kuipers announced yesterday that there is full financing for the construction of the PALLAS reactor. This is a major step towards realising the new facility in Petten, North Holland. The construction of a new reactor would be…
“Advancing Healthcare” Exploring the Frontiers of Nuclear Medicine In the field of healthcare innovation, nuclear medicine and radiopharmaceuticals stand out for their remarkable contributions to diagnosis and treatment. These technologies offer personalized approaches and targeted therapies, which are revolutionizing patient care. However, to ensure access to these cutting-edge treatments for all, it’s crucial to support…
NRG|PALLAS and Curium Expand Cooperation in Lu-177 Production NRGIPALLAS (ENS Corporate Member) and Curium have signed a long-term agreement to expand the current cooperation to include the production of lutetium-177 (Lu-177). This agreement will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year. Curium and NRG…
Framatome Advances Towards Producing Lu-177 In Romania Framatome (ENS Corporate Member) and Nuclearelectrica have announced the successful outcome of the feasibility study which assessed the possibility of producing medical isotope Lutetium-177 (Lu-177) at the Cernavoda nuclear power plant in Romania. The two companies have now launched the implementation of the project, covering detailed engineering, procurement,…
NRG|PALLAS and TAG1 Inc. Partner To Expand Pb-212 Production NRGIPALLAS (ENS Corporate Member) and TAG1 Inc. have signed a multi-year partnership to secure a critical supply of radium-224 for the production of lead-212 (Pb-212) isotope. This agreement aims to strengthen the supply chain for innovative radiopharmaceutical cancer treatments, including Targeted Alpha Therapies (TATs), which hold great…
Framatome To Study Medical Radioisotopes Production At Argentinian NPPs Framatome (ENS Corporate Member) and Nucleoeléctrica Argentina have signed an agreement to conduct a pre-feasibility study on installing systems for producing short-lived radioisotopes, such as Lutetium-177, at the nuclear power plants operated by the Argentine company: Atucha I, Atucha II, and Embalse. The study is expected…